Jean-Charles Soria, Senior Vice President of Oncology within Global Development at Amgen, posted the following on LinkedIn:
“Delving into the future of cancer treatment with new ADC formats: Bispecific ADCs targeting multiple antigens, Dual-drug ADCs combining different cytotoxins, Probody-drug conjugates for enhanced tumor specificity, Immune-stimulating ADCs, Protein-degrader ADCs & other formats pushing the frontiers of oncology.”
Read further.
Source: Jean-Charles Soria/LinkedIn